# Cansativa Financial Model B2B cannabis distribution and ecosystem platform enabling dispensaries, suppliers, growers, and governments to operate in regulated cannabis markets. - Canonical: https://finamodel.com/startups/cansativa - Excel download: https://finamodel.com/startup-models/cansativa.xlsx - Category: Health-tech - Model type: Marketplace / GMV - Funding round: Series B - Funding: $15M - Founded: 2022 - Geography: Germany primary market; broader European expansion anticipated via legalization "domino effect" [DECK, slide 4]. - Customer: B2C ## About the company Cansativa is a B2B cannabis distribution and ecosystem platform for regulated markets, connecting suppliers, growers, dispensaries, pharmacies, and governments. It focuses on the operational infrastructure required to move medical cannabis compliantly. Current revenue comes primarily from import and wholesale distribution, supported by an exclusive government contract for domestic German medical cannabis. A broader platform layer can add services, but product volume and spread remain the core economics. The model should forecast kilograms distributed, wholesale price, product cost, contract minimums, and gross margin by channel. Inventory, working capital, regulatory compliance, and government-contract concentration should be separated from any future platform fees. ## What's included - 5-year monthly revenue build with stage-appropriate growth assumptions - Full P&L, headcount plan, and operating-expense schedule - Cash-flow statement, runway, and burn-rate tracking - Valuation via exit multiple with a DCF cross-check - Returns analysis with MOIC and IRR - Unit economics including CAC, LTV, payback, and cohort retention ## Product & value proposition - Platform that handles licensing, regulatory compliance, supply/procurement, and distribution on behalf of cannabis dispensaries and B2B partners. - Exclusive/monopolist partner of the Federal Republic of Germany for domestic medical cannabis distribution for the next four years. - Three target verticals: (1) Health / medical, (2) Narcotics/pharmaceutical warehousing and distribution, (3) Wellbeing, food & retail. - Positioning as the "360° holistic cannabis ecosystem" - connecting suppliers, dispensaries, growers, and governmental bodies. ## Market - German legal medical cannabis market 2021: 15 tons. - German illegal cannabis market 2021: >400 tons. - Post-legalization annual addressable cannabis market (Germany, 24–36-month horizon): >4bn EUR. - European context: 750mn population, >13 trillion EUR economic power. - Comparable market reference: Colorado (5mn people) generated $2.3bn in cannabis sales in 2021. Germany (83mn people, GDP $3.84 trillion) implies materially larger potential. - >10bn EUR narcotics services market in Europe. - No SAM/SOM breakdowns or Cansativa's specific share targets provided. ## Revenue model - Primary current revenue: Import and wholesale distribution of medical cannabis to pharmacies, dispensaries, and healthcare providers (B2B). Earns a margin on product sold (volume × price spread). - Exclusive government contract for distribution of domestic German medical cannabis - guaranteed offtake for 4 years. - Platform/ecosystem layer implied (technology, compliance, partner onboarding) - SaaS or take-rate revenue model hinted at but not quantified. - Recreational market anticipated as a second revenue stream post-legalization; investment slide separates MEDICAL (Scale and Grow) and RECREATIONAL (Prepare) spend. - No pricing, take rates, or per-unit margins disclosed in deck. ## Traction & metrics - Revenue: Bar chart (slide 10) shows FY2018–FY2021 actuals with clear upward trajectory and steeper planned growth FY2022–FY2025. No absolute EUR values labeled on chart axes - cannot read specific figures. - Described as having a "proven track record of significant top-line revenue growth and efficient capital allocation". - "Recurring thousands of customer interactions" referenced as market positioning evidence. - No customer count, revenue figures (EUR), GMV, or retention rate provided in extractable text or legible chart labels. ## Competition / moat - Moat 1: Government exclusivity - monopolist/exclusive partner of the Federal Republic of Germany for domestic medical cannabis distribution for 4 years. - Moat 2: First-mover in a highly regulated, licensed market - very high regulatory barriers to entry. - Moat 3: Broadest product portfolio and established supplier/customer relationships. - No named competitors referenced; competitive landscape slide not present. ## Team & funding ask / use of funds - Team description: "Top-notch leadership with a proven track record as first-mover in highly regulated & licensed industries and to scale a cannabis business in Europe". No named individuals, bios, or org chart shown. - Funding ask: $15mn USD. - Use of funds split into two buckets: - MEDICAL - Scale and Grow: (1) Double headcount in IT/technology, sales, operations; (2) Connect further B2B-platform partners (suppliers, customers); (3) Platform user acquisition and marketing. - RECREATIONAL - Prepare: Technology and platform advancement for anticipated recreational market. ## Recommended financial model - **Archetype + why:** B2B Distribution / Wholesale Revenue model with a Platform Ecosystem overlay. Core revenue driver is volume-based (kg/tons of cannabis distributed × wholesale margin), supplemented by a government contract fixed/minimum offtake and a nascent platform fee layer. This is not SaaS and not pure marketplace GMV - it is closer to a specialty pharmaceutical distributor P&L with a regulatory monopoly wedge. A 3-statement model is appropriate given the capital raise and need to show EBITDA path. - **Forecast horizon & granularity:** FY2022–FY2025 (4 years), matching the deck's own outlook period. Annual granularity for the base model; monthly for the first 12 months (cash management given the raise). Medical and Recreational modeled as separate segments. - **Key drivers & assumptions:** - Medical cannabis volume distributed (tons/year): FY2021 baseline ~15 tons German legal market; assume Cansativa captures 60–80% of legal market given exclusive government contract. - Wholesale price per kg:. - Distribution/wholesale gross margin %:. - Platform/ecosystem fee revenue:. - Headcount growth: double within "next months" per the raise plan; model 2× headcount in FY2022 then linear growth thereafter. - OpEx: Sales & marketing, IT/tech, operations grow in line with headcount. - Recreational revenue: zero until post-legalization; model as a scenario toggle starting FY2024. - CapEx: Minimal (asset-light platform); warehouse/logistics may require some. - German market post-legalization size: >4bn EUR TAM; Cansativa addressable share. - **Scenarios (Base / Bull / Bear - which variables flex):** - Base: Medical monopoly contract sustained at 60% market share; recreational legalization by 2024; platform fees ramp from 2023. - Bull: Legalization accelerates (early 2023); Cansativa wins dominant recreational distribution; rapid EU geographic expansion; margin expansion from platform mix shift. - Bear: Legalization delayed beyond 2025; medical market competition increases post-exclusivity; margin compression from regulatory pricing controls. - **Required sheets / outputs:** 1. Assumptions (all drivers in one place, toggle for scenarios) 2. Medical Segment P&L (volume × price × margin) 3. Recreational Segment P&L (gated by legalization trigger) 4. Platform/Ecosystem Revenue build 5. Headcount & OpEx schedule 6. Consolidated P&L (Revenue → EBITDA → EBIT) 7. Cash Flow & Runway (linked to $15mn raise) 8. Balance Sheet (light - mainly working capital and cash) 9. KPI dashboard: Revenue (EUR), Volume (tons), Gross Margin %, EBITDA %, Runway (months) ## Frequently asked questions ### Is the Cansativa financial model free? Yes. The Cansativa model is a free Excel download with live formulas. ### Can I change the assumptions? Yes. The workbook is editable and its live formulas recalculate when assumptions change.